Dr. Yoon on Immunotherapy in Gastric Cancer

Harry H. Yoon, MD
Published: Monday, Sep 25, 2017



Harry H. Yoon, MD, associate professor of oncology, Mayo Clinic, discusses the benefits demonstrated with nivolumab (Opdivo) and pembrolizumab (Keytruda) for patients with gastric cancer.

The degree of benefit for nivolumab is higher than what has been seen with other biologic agents and was well tolerated for patients with gastric cancer, explains Yoon.

Additionally, the PD-1 inhibitor pembrolizumab showed a similar level of benefit or response in a single-arm phase II study as nivolumab, states Yoon. Now, there are 2 different agents targeting PD-1 showing similar efficacy. The FDA recently approved pembrolizumab for the treatment of patients with PD-L1–positive recurrent or advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received 2 or more lines of chemotherapy, including fluoropyrimidine- and platinum-containing chemotherapy, and, if appropriate, HER2/neu-targeted therapy.
 


Harry H. Yoon, MD, associate professor of oncology, Mayo Clinic, discusses the benefits demonstrated with nivolumab (Opdivo) and pembrolizumab (Keytruda) for patients with gastric cancer.

The degree of benefit for nivolumab is higher than what has been seen with other biologic agents and was well tolerated for patients with gastric cancer, explains Yoon.

Additionally, the PD-1 inhibitor pembrolizumab showed a similar level of benefit or response in a single-arm phase II study as nivolumab, states Yoon. Now, there are 2 different agents targeting PD-1 showing similar efficacy. The FDA recently approved pembrolizumab for the treatment of patients with PD-L1–positive recurrent or advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received 2 or more lines of chemotherapy, including fluoropyrimidine- and platinum-containing chemotherapy, and, if appropriate, HER2/neu-targeted therapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x